Ado-trastuzumab emtansine

November 6, 2019

First Patient Dosed in Phase 3 Trial of Tucatinib-Kadcyla Combo for Advanced HER2-Positive Breast Cancer

News

A Phase 3 trial exploring a combination of Seattle Genetics‘ tucatinib plus standard Kadcyla (ado-trastuzumab emtansine) in people with advanced HER2-positive breast cancer has dosed its first participant, the company ... Read more

May 10, 2019

Kadcyla Approved in US for Some HER2-positive Early Breast Cancer Patients

News

The U.S. Food and Drug Administration (FDA) has extended the use of Genentech‘s Kadcyla (ado-trastuzumab emtansine) as an adjuvant (post-surgery) treatment for some patients with HER2-positive, early-stage breast cancer, the company announced. ... Read more

February 15, 2019February 18, 2019

Experimental Compound Could Broaden HER2-targeted Approach to BC

News

By targeting small regulatory molecules called microRNAs (miRNAs), researchers were able to reprogram breast cancer cells and render them sensitive to HER2-targeting medicines, such as Herceptin (trastuzumab) and Kadcyla (ado-trastuzumab emtansine), a study ... Read more

August 23, 2016August 23, 2016

Kadcycla Effective in Advanced Breast Cancer Patients Already Given Perjeta

News

Kadcyla (ado-trastuzumab emtansine, or T-DM1) may benefit HER2-positive metastatic breast cancer patients whose disease continues to progress despite prior treatment with Herceptin (trastuzumab) and Perjeta (pertuzumab), according to the results ... Read more